For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 39,054 | |||
| General and administrative expenses | 17,835 | |||
| Total operating expenses | 56,889 | |||
| Loss from operations | -56,889 | |||
| Interest income and other, net | 5,851 | |||
| Total other income | 5,851 | |||
| Net loss | -51,038 | |||
| Net unrealized gain (loss) on marketable securities | -110 | |||
| Total comprehensive loss | -51,148 | |||
| Basic EPS | -1.58 | |||
| Diluted EPS | -1.58 | |||
| Basic Average Shares | 32,345,525 | |||
| Diluted Average Shares | 32,345,525 | |||
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)